Minerva Neurosciences (NERV) AI Stock Analysis

• Market Cap: $192.57M
• Dividend Yield: N/A
• Average Volume (3M): 465.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: N/A
• EPS Growth: -323.61%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 43,274,400
• 10 Day Avg. Volume: 1,362,901
• 30 Day Avg. Volume: 465,600
• PEG Ratio: -0.11
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -42.37K
• Enterprise Value/Ebitda: -5.62
• 1Y Price Target: $4.50
• Price Target Upside: 4.17% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $4.00 ▼(-7.41% Downside)

The score is held back primarily by weak financial fundamentals (ongoing losses, sustained cash burn, and negative equity). Technicals are moderately supportive with price above key moving averages and positive MACD, while corporate events add support via improved financing capacity (though with dilution risk). Valuation is constrained by negative earnings and no dividend support.

Positive Factors

Innovative Product Pipeline

Minerva Neurosciences' focus on innovative therapies for CNS disorders positions it well in a niche market with high unmet needs, potentially leading to significant future revenue if clinical trials are successful.

Strategic Partnerships Potential

The company's strategy to secure licensing agreements and partnerships could provide essential funding and market access, enhancing its ability to bring products to market and generate revenue.

Focus on CNS Disorders

By targeting CNS disorders, Minerva Neurosciences addresses a growing market with significant demand for new treatments, potentially leading to strong market positioning if successful.

Negative Factors

Negative Equity

Negative equity indicates financial distress, as liabilities exceed assets, posing a risk to solvency and limiting the company's ability to invest in growth or withstand financial shocks.

Lack of Revenue

The absence of revenue generation highlights operational challenges and reliance on external funding, which may hinder long-term sustainability and growth prospects.

Negative Cash Flow

Consistently negative cash flow indicates operational inefficiencies and a reliance on external financing, which could strain financial resources and limit strategic flexibility.

Minerva Neurosciences Business Overview & Revenue Model

Company Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Minerva Neurosciences makes money through the development and potential future commercialization of its proprietary drug candidates, which are aimed at treating central nervous system disorders. The company seeks to advance its drug candidates through clinical trials, obtain regulatory approval, and eventually bring these therapies to market. Revenue generation is expected to come from product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. However, as a clinical-stage company, Minerva Neurosciences currently does not have significant revenue from product sales and relies on funding through public and private investments to support its research and development activities.

Minerva Neurosciences Financial Statement Overview

Summary

Overall, Minerva Neurosciences faces significant financial challenges. The income statement reflects a lack of revenue generation, coupled with ongoing operational losses. The balance sheet shows negative equity, raising solvency issues. Cash flow analysis indicates a consistent inability to generate positive operating cash flows, underscoring operational inefficiencies. These factors combined suggest a high-risk financial position with urgent need for strategic changes to improve financial health.

Income Statement

The income statement shows significant challenges. The company has not reported any revenue since 2020, indicating a lack of sales or operational income. Net income has been highly volatile, with significant losses in recent years, except for a positive net income in 2024, which seems driven by non-operational factors. The absence of revenue growth and negative profitability margins signal financial instability.

Balance Sheet

The balance sheet reflects substantial financial distress with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, highlighting severe financial leverage issues. Total liabilities greatly exceed assets, and the equity ratio is negative, pointing to potential solvency concerns.

Cash Flow

Cash flows show persistent negative free cash flow, indicating the company is not generating sufficient cash from operations to cover its expenses. Operating cash flow has been consistently negative, and while there was a positive financing cash flow in some years, this indicates reliance on external financing. The inability to generate positive cash flow raises concerns about the company's operational efficiency and financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	41.18M
Gross Profit	-1.36K	0.00	0.00	0.00	0.00	41.18M
EBITDA	-10.27M	6.02M	-21.69M	-24.69M	-45.28M	2.12M
Net Income	-10.27M	1.44M	-30.01M	-32.11M	-49.91M	1.94M
Balance Sheet
Total Assets	28.09M	37.14M	56.90M	55.09M	77.12M	57.63M
Cash, Cash Equivalents and Short-Term Investments	12.29M	21.36M	40.91M	36.09M	60.76M	25.36M
Total Debt	0.00	0.00	0.00	0.00	0.00	111.23K
Total Liabilities	62.67M	62.84M	85.36M	75.11M	69.15M	4.96M
Stockholders Equity	-34.58M	-25.69M	-28.46M	-20.02M	7.98M	52.66M
Cash Flow
Free Cash Flow	-10.13M	-19.55M	-14.78M	-24.66M	-24.60M	-33.82M
Operating Cash Flow	-10.13M	-19.55M	-14.78M	-24.65M	-24.60M	-33.82M
Investing Cash Flow	0.00	0.00	0.00	-16.33K	0.00	24.53M
Financing Cash Flow	-45.17K	0.00	19.60M	-5.00	60.00M	13.24M

Minerva Neurosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NERV, the sentiment is Positive. The current price of 4.32 is above the 20-day moving average (MA) of 4.14, above the 50-day MA of 4.00, and above the 200-day MA of 2.53, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 54.67 is Neutral, neither overbought nor oversold. The STOCH value of 64.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NERV.

Minerva Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NERV	50 Neutral	$192.57M	-2.33	―	―	―	-323.61%
BLRX	48 Neutral	$13.31M	-2.09	-22.03%	―	-41.76%	87.36%
PULM	43 Neutral	$8.62M	-1.38	-79.47%	―	-99.97%	35.59%
CMMB	39 Underperform	$11.02M	-0.98	-73.63%	―	―	53.19%

Minerva Neurosciences Corporate Events

Minerva Neurosciences Shareholders Approve Key Governance Measures

At its annual meeting of stockholders held on December 22, 2025, Minerva Neurosciences, Inc. secured broad shareholder approval for a series of measures expanding its equity and capital flexibility, including an amendment to its 2013 Equity Incentive Plan to add 12,500,000 shares for potential issuance. Stockholders re-elected two directors to terms running until the 2028 annual meeting, approved doubling the company’s authorized common shares from 125 million to 250 million, authorized the issuance of common stock upon conversion of Series A Convertible Voting Preferred Stock in line with Nasdaq rules, endorsed executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025, collectively reinforcing management’s governance, financing capacity and incentive structures.

The most recent analyst rating on (NERV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Minerva Neurosciences Expands Board Amid Fundraising Effort

On November 14, 2025, Minerva Neurosciences appointed Dr. Inderjit Kaul to its Board of Directors as part of an expansion following a securities purchase agreement. Dr. Kaul, who brings extensive experience in drug development, will also serve as a consultant to assist with the clinical development of roluperidone, a treatment for negative symptoms of schizophrenia. This appointment aligns with Minerva’s recent $200 million fundraising effort to support a Phase 3 trial of roluperidone, aiming to address a significant unmet need in schizophrenia treatment.

The most recent analyst rating on (NERV) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.

Minerva Neurosciences Secures $200M for Drug Trials

On October 21, 2025, Minerva Neurosciences announced a securities purchase agreement with accredited investors to raise up to $200 million through a private placement. This funding will support the Phase 3 confirmatory trial of roluperidone, the resubmission of its New Drug Application, and preparation for a potential U.S. commercial launch. The agreement includes an initial $80 million upfront and additional proceeds contingent on warrant exercises. The company plans to appoint new directors with schizophrenia clinical trial experience to its board to strengthen its clinical operations.

The most recent analyst rating on (NERV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.